drugset / Trial / NCT00231192
Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes
Withdrawn
Children's Hospital of Philadelphia
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will test the hypothesis that oral repaglinide is equivalent to insulin in the treatment of new-onset CFRD in adolescents. In addition, successful treatment of CFRD with repaglinide will improve nutritional status, ameliorate declines in pulmonary function, and will not have a negative impact upon quality of life.
Timeline
- Start
- 2005-10
- Primary completion
- —
- Completion
- 2007-08
Outcome
Outcome not reported
Stopped (Enrollment): “Unable to recruit any subjects”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Insulin | Protein / enzyme biologic | — | — |
| Subject | Repaglinide | Small molecule | — | Oral |